Harvard Doc Upends Psychiatry Playbook

File drawer with tabs labeled for mental health disorders — Photo: Olivier Le Moal / Shutterstock

A Harvard psychiatrist built a 30-year career treating the brain, then staked his reputation on a simple idea: what you eat may matter as much as any pill you take.

Story Snapshot

Dr. Chris Palmer founded MH², a health care model merging metabolic and mental health treatment.
He also directs the Metabolic and Mental Health Program at McLean Hospital, a top-ranked psychiatric institution.
His approach uses ketogenic diets to treat depression, bipolar disorder, and schizophrenia.
Early studies show promise, but researchers say large controlled trials are still needed.

A Psychiatrist Bets His Career On Food

Dr. Christopher Palmer spent almost three decades practicing psychiatry at Harvard Medical School and McLean Hospital. Somewhere along the way, he started asking a question most of his colleagues weren’t asking. What if mental illness isn’t just a chemical imbalance in the brain? What if it’s also a metabolic problem, tied to how the body’s cells make and use energy?

That question led him to found MH², a company built on a single mission. It treats mental health and metabolic health as two sides of the same coin, not separate problems handled by separate doctors.

Palmer didn’t stop at theory. At McLean Hospital, he built and now runs the Metabolic and Mental Health Program, where he has pioneered the use of medical ketogenic diets to treat psychiatric patients. His pitch is bold. He argues metabolism belongs next to brain chemistry and psychology as a pillar of mental health care, not an afterthought.

Why The Ketogenic Diet Became His Tool Of Choice

The ketogenic diet isn’t new. Doctors have used it for a century to control epileptic seizures, and it’s considered an established, evidence-based treatment for that condition. Palmer’s innovation was asking whether the same metabolic shift that calms a seizing brain might also ease depression, bipolar disorder, and schizophrenia.

His clinical work claims real results. Patients with severe, treatment-resistant psychiatric conditions have seen symptoms improve after adopting the diet, according to Palmer’s own accounts of his practice. For families who’ve watched loved ones cycle through medication after medication with little relief, that kind of claim lands hard. It offers something medication alone hasn’t always delivered: hope tied to something they can control at the dinner table.

What The Broader Research Actually Shows

Palmer isn’t a lone voice shouting into the void. A Stanford Medicine pilot study found that patients on a ketogenic diet saw both their metabolic health and their psychiatric symptoms improve, with participants showing meaningful gains on standard psychiatric rating scales. Stanford researchers have continued building on that work, framing ketogenic therapy as a genuine option for people with serious mental illness.

Other reviews back a more cautious version of the same conclusion. One analysis found medically supervised carbohydrate restriction to be a simple, safe intervention worth considering alongside standard treatment. Another, reviewing trials across depression, bipolar disorder, and schizophrenia, found real evidence of benefit but flagged a problem common in early-stage medical research: uncontrolled trials, confounding factors, and expectation bias make it hard to prove the diet itself is driving the improvement.

This pattern shows up again and again in medicine. A promising idea starts with a persuasive clinician, a handful of case studies, and patients who swear by it. Then it spends years fighting for large, rigorous trials before it earns a permanent place in standard care. Ketogenic psychiatry is squarely in that middle stage right now, with genuine momentum but not yet the gold-standard proof that changes national guidelines.

The Case For Taking This Seriously

Skepticism toward slow-moving institutions isn’t unreasonable. Patients with schizophrenia and bipolar disorder often endure medications with brutal side effects, including major weight gain, while waiting for research bureaucracies to catch up to what clinicians see in their own offices. Palmer’s push to treat metabolism as central to mental health, not peripheral, reflects a practical, common-sense instinct: fix the body’s fuel system, and the mind may follow.

That instinct deserves respect precisely because it’s testable, low-cost, and already showing measurable results in supervised settings. A systematic review of carbohydrate-restricted diets found they pose no added psychological risk compared to other diets, with benefits appearing after twelve weeks or more of consistent use. For patients and families tired of waiting on slow science, that’s a meaningful signal, even as bigger trials continue.

Palmer’s bigger bet is that MH² becomes a model other hospitals copy: one where a psychiatrist and a nutrition-focused metabolic specialist sit in the same room with a patient, instead of working in separate silos. Whether or not every claim survives the next decade of trials, the underlying premise, that the body and brain run on the same fuel, is hard to argue with.